ANGLE PLC (LON:AGL) has signed a contract with the University of Manchester through Cancer Research UK that will see its breakthrough liquid biopsy system Parsortix used in research trials.
Andrew Newland, chief executive, tells Proactive Investors: 'This is really important. It comes after four years of working to develop the tests and on the strength of that data they [the University of Manchester] now want to incorporate it for routine use in their clinical laboratory.'
He says Parsortix is already being used in 10 clinical trials, and that the deal is with 'one of the foremost customers that we could possibly hope for,' adding that this should give the rest of the market confidence, and 'turbocharge' its sales in research use.
Meet Eco (Atlantic) Oil & Gas Ltd and Bushveld Minerals Limited at our event, London, 13 June 2016. Register here ' Share Facebook if (typeof urlShortener == 'undefined') { var urlShortener = { generate: function(){ $.get('/swift/tinyUrl?url=http%3A%2F%2Fwww.proactiveinvestors.co.uk%2Fcompanies%2Fstocktube%2F5073%2Fangle-chief-sees-parsotix-sales-turbocharged-by-manchester-uni-deal-5073.html', function( url ) { $('.twitter.tweet').attr('onclick', 'popUp = window.open(\'https://twitter.com/intent/tweet?url=' + url + '&text=%23AGL+ANGLE+chief+sees+Parsotix+sales+%E2%80%9Cturbocharged%E2%80%9D+by+Manchester+Uni+deal+-+%40parsortix&via=proactive_uk\', \'popupwindow\', \'scrollbars=yes,width=800,height=400\');popUp.focus();return false'); }); } } urlShortener.generate(); } Twitter
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.